Fed. Circ. Wary Of Reviving Gilead's Lexiscan IP Suit
A Federal Circuit panel seemed skeptical Tuesday that Gilead Sciences and Astellas were wrongly barred from responding to amendments Hospira made "at the eleventh hour" to an abbreviated new drug application...To view the full article, register now.
Already a subscriber? Click here to view full article